PhII ICb With/Without Erbitux in MBC Pts
NCT00248287
·
clinicaltrials.gov ↗
PHASE2
Phase
ACTIVE_NOT_RECRUITING
Status
154
Enrollment
INDUSTRY
Sponsor class
Conditions
Metastatic Breast Cancer
Interventions
DRUG:
Irinotecan + Carboplatin
DRUG:
irinotecan + Carboplatin + erbitux
Sponsor
US Oncology Research
Collaborators
[object Object]
[object Object]